Eledon submits FDA IND for tegoprubart islet cell transplant trial in type 1 diabetes
ELDN•FDA IND submission and trial plans
- Eledon submitted an IND to the FDA for a registrational tegoprubart trial in islet cell transplantation for type 1 diabetes.
- The company reaffirmed plans to start its global Phase 3 LEGACY kidney transplant trial in Q4 2026.
